Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Peptide injections for weight loss are a broad category, but only one class has strong clinical evidence: GLP-1-based medicines such as semaglutide and tirzepatide. Other injectable peptides marketed for fat loss, including AOD-9604, CJC-1295, ipamorelin, MOTS-c, and BPC-157, are not FDA-approved for weight loss and lack robust human obesity trials.[1][2][12]
Quick facts: peptide injections for weight loss
Peptide injections are medicines or research compounds made from short chains of amino acids. For weight loss, the best-supported options are prescription GLP-1-based medications, with trial results reported over 56 to 72 weeks and with side effects that need medical monitoring.[1][2][3][4][5][6]
- What they are: Peptides are small chains of amino acids. Some act like body signals, including incretin hormones such as GLP-1 and GIP.[1][2]
- Which are FDA-approved for chronic weight management: Wegovy (semaglutide, a GLP-1 receptor agonist), Zepbound (tirzepatide, a dual GLP-1/GIP receptor agonist), and Saxenda (liraglutide, a GLP-1 receptor agonist) are FDA-approved for certain adults with obesity or overweight with a weight-related condition.[1][2][3]
- Which are not FDA-approved for weight loss: AOD-9604, CJC-1295, ipamorelin, MOTS-c, BPC-157, and tesamorelin are not FDA-approved for general weight loss. Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, which is a different use.[11][12]
- Expected results: Average trial results vary by medicine, dose studied, follow-up time, diet and activity support, side effects, and who was enrolled. Individual results vary.[4][5][6]
- Access: Prescription GLP-1-based medications require a licensed clinician to review medical history, medications, lab needs, contraindications, and follow-up plans.[1][2][3]
What are peptide injections for weight loss?
Peptide injections for weight loss can mean two very different things: FDA-approved prescription medications used for chronic weight management, or research-style peptides marketed online for body composition. That difference matters because the evidence, safety review, and legal status are not the same.[1][2][3][12]
Peptides vs. proteins vs. hormones
A peptide is a short chain of amino acids. A protein is a longer, more complex chain. Some hormones are peptides, meaning they act as chemical messengers in the body. GLP-1 and GIP are incretin hormones released by the gut after eating, and GLP-1-based medicines act on these pathways.[1][2]
Semaglutide (Wegovy, Ozempic; a GLP-1 receptor agonist; also available as compounded semaglutide through licensed 503A pharmacies when legally appropriate) is a peptide medication. Tirzepatide (Zepbound, Mounjaro; a dual GLP-1/GIP receptor agonist; also available as compounded tirzepatide through licensed 503A pharmacies when legally appropriate) is also peptide-based.[1][2][7][8][9]
Why 'peptide' has become a marketing term
The word peptide is now used in ads for many injections, including compounds that are not FDA-approved for weight loss. That can make proven prescription medicines and early-stage research peptides sound equal, even when they are not. The American Medical Association has warned patients to be careful with injectable peptides sold for wellness or body composition without strong evidence or clear regulatory oversight.[12]
Do peptide injections actually work for weight loss?
Peptide injections can work for weight loss when they are GLP-1-based prescription medicines studied in large clinical trials, but the phrase covers many products. The strongest evidence comes from trials lasting about 1 year or more, and the same studies also report side effects such as nausea, vomiting, diarrhea, constipation, and discontinuation due to adverse events.[4][5][6]
What the evidence shows for GLP-1 receptor agonists
In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly plus lifestyle support and lost an average of 14.9% of body weight at 68 weeks, compared with 2.4% with placebo. Gastrointestinal side effects were common, and more people stopped treatment because of adverse events in the semaglutide group than in the placebo group.[4]
In the SURMOUNT-1 trial, participants received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle support and lost an average of 15.0% to 20.9% of body weight at 72 weeks, compared with 3.1% with placebo. Nausea, diarrhea, and constipation were common, and some participants stopped treatment due to adverse events.[5]
In the SCALE Obesity and Prediabetes trial, participants received liraglutide 3.0 mg once daily plus lifestyle support and lost an average of 8.0% of body weight at 56 weeks, compared with 2.6% with placebo. Gastrointestinal side effects were more common with liraglutide, and serious risks are described in the FDA label.[3][6]
What the evidence shows, and does not show, for other peptides
AOD-9604, CJC-1295, ipamorelin, MOTS-c, and BPC-157 are often marketed for fat loss or body composition, but they are not FDA-approved for weight loss. Some have animal, lab, or small human studies for other questions, but they do not have the same large, long-term weight-loss trial evidence as semaglutide, tirzepatide, or liraglutide.[12]
Which peptide injections are used for weight loss?
Weight-loss peptide injections include FDA-approved GLP-1-based medicines, compounded GLP-1 options when allowed, and research peptides that are not FDA-approved for this use. The key split is whether the product has FDA-reviewed labeling for chronic weight management, including the approved dose schedule, risks, contraindications, and use criteria.[1][2][3][9][12]
| Peptide or medicine | Drug class or category | FDA status for weight loss | Evidence summary | Key safety notes |
|---|---|---|---|---|
| Semaglutide: Wegovy, Ozempic, compounded semaglutide | GLP-1 receptor agonist | Wegovy is FDA-approved for chronic weight management in eligible patients; Ozempic is FDA-approved for type 2 diabetes, not weight loss; compounded semaglutide is not FDA-approved.[1][7][9] | STEP 1 showed 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg once weekly plus lifestyle support.[4] | Common GI side effects; boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.[1] |
| Tirzepatide: Zepbound, Mounjaro, compounded tirzepatide | Dual GLP-1/GIP receptor agonist | Zepbound is FDA-approved for chronic weight management in eligible adults; Mounjaro is FDA-approved for type 2 diabetes, not weight loss; compounded tirzepatide is not FDA-approved.[2][8][9] | SURMOUNT-1 showed 15.0% to 20.9% mean weight loss at 72 weeks with tirzepatide 5 mg, 10 mg, or 15 mg once weekly.[5] | Common GI side effects; boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.[2] |
| Liraglutide: Saxenda | GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and certain adolescents.[3] | SCALE showed 8.0% mean weight loss at 56 weeks with liraglutide 3.0 mg once daily plus lifestyle support.[6] | Daily injection; common GI side effects; boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.[3] |
| Tesamorelin | Growth hormone-releasing factor analog | Not FDA-approved for general weight loss; FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.[11] | Studied for a specific HIV-associated lipodystrophy indication, not routine obesity treatment.[11] | Can affect glucose and fluid balance; not a substitute for GLP-1-based obesity treatment.[11] |
| AOD-9604, CJC-1295, ipamorelin, MOTS-c, BPC-157 | Research or wellness-marketed peptides | Not FDA-approved for weight loss.[12] | No large, FDA-reviewed obesity trials showing long-term weight-loss benefit like GLP-1-based medications.[12] | Quality, sterility, side effect, and regulatory risks may be higher when products are obtained outside licensed medical care.[12] |
Semaglutide: Wegovy and Ozempic
Wegovy (semaglutide) is FDA-approved for chronic weight management in eligible people with obesity or overweight with a weight-related condition. The FDA-approved Wegovy starting dose is 0.25 mg once weekly for 4 weeks, with labeled escalation to a maintenance dose of 2.4 mg once weekly when tolerated; this is label information, not personal dosing advice.[1]
Ozempic (semaglutide) is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes, not as a weight-loss medication, though weight change can occur in diabetes trials. Ozempic and Wegovy share semaglutide as the active ingredient but have different labels and use cases.[1][7]
Tirzepatide: Zepbound and Mounjaro
Zepbound (tirzepatide) is FDA-approved for chronic weight management in eligible adults. The FDA-approved Zepbound starting dose is 2.5 mg once weekly for 4 weeks, followed by labeled dose escalation; this is FDA label information, not an instruction for any individual reader.[2]
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, not weight loss. Tirzepatide activates both GIP and GLP-1 receptors, which is why it is described as a dual GLP-1/GIP receptor agonist.[2][8]
Liraglutide: Saxenda
Saxenda (liraglutide) is an FDA-approved GLP-1 receptor agonist for chronic weight management in eligible adults and certain adolescents. The FDA-approved Saxenda label describes a 0.6 mg once-daily starting dose and escalation to 3.0 mg once daily; this is label information for clinician-supervised care, not self-directed dosing advice.[3]
Compounded semaglutide and tirzepatide via 503A pharmacies
Compounded semaglutide and compounded tirzepatide are custom-prepared versions that may be dispensed by licensed 503A compounding pharmacies when federal and state law allow. Compounded drugs are not FDA-approved, and FDA says patients should obtain compounded GLP-1 medicines only with a prescription from a licensed clinician and through appropriate pharmacy channels.[9]
AOD-9604, CJC-1295, ipamorelin, tesamorelin, MOTS-c, and BPC-157
AOD-9604, CJC-1295, ipamorelin, MOTS-c, and BPC-157 are not FDA-approved for weight loss. Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, but that does not mean it is approved for general weight loss. These products should not be treated as proven substitutes for FDA-approved obesity medications.[11][12]
For BPC-157, published preclinical work has used animal dosing models rather than FDA-reviewed obesity treatment protocols; for example, Sikirić et al. described experimental BPC-157 dosing in rats, but BPC-157 is not FDA-approved for weight loss or tissue repair in humans.[13] For MOTS-c, early human research has focused on safety and pharmacology rather than an FDA-approved weight-loss indication, so it should be viewed as investigational for body composition.[14]
Are peptide injections the same as Ozempic?
Ozempic is a peptide medication because semaglutide is peptide-based, but not every peptide injection is Ozempic. The important difference is FDA-reviewed use: Ozempic is approved for type 2 diabetes, while Wegovy uses semaglutide for chronic weight management under a different FDA label with a 2.4 mg once-weekly maintenance dose.[1][7]
Ozempic and Wegovy are peptide medications
Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. They share the same active ingredient but have different FDA-approved indications, labeling, pens, and clinical use cases. A clinician reviews the diagnosis, goals, risks, and access pathway before choosing a medication.[1][7]
How GLP-1s differ from research peptides
GLP-1 medications have FDA labels that describe who they are for, what outcomes were studied, and what risks are known. Research peptides marketed for fat loss often do not have large obesity trials, FDA-approved labeling for weight loss, or the same quality controls when sold outside licensed pharmacy channels.[1][2][3][12]
How do GLP-1 peptide injections work in the body?
GLP-1 peptide injections work by acting on incretin pathways involved in appetite, stomach emptying, and blood sugar control. These effects can support weight loss over months, but they can also cause GI side effects and are not appropriate for people with certain contraindications.[1][2][3]
Appetite and food noise
GLP-1 receptor agonists act in brain pathways involved in appetite and fullness. Some people describe less hunger or less constant thinking about food, sometimes called food noise. This effect can help reduce calorie intake, but nausea or reduced appetite can become uncomfortable and should be monitored.[1][2][4][5]
Slowed gastric emptying
GLP-1 medicines slow how quickly food leaves the stomach. This can help people feel full longer, but it can also lead to nausea, vomiting, bloating, constipation, or reflux symptoms. FDA labels also note that delayed stomach emptying may affect the absorption of some oral medicines.[1][2][3]
Blood sugar and insulin effects
GLP-1 and GIP pathways help the body release insulin in response to meals and reduce glucagon when appropriate. This is one reason semaglutide and tirzepatide are also used in diabetes care under certain brand labels. People using insulin or sulfonylureas may have a higher risk of low blood sugar and need clinician monitoring.[1][2][7][8]
How much weight can you expect to lose?
Expected weight loss depends on the medication, health history, adherence, side effects, nutrition, activity, sleep, and follow-up care. In trials, average results ranged from about 8% to 21% body-weight loss across liraglutide, semaglutide, and tirzepatide studies, while side effects and discontinuation also occurred.[4][5][6]
| Medication studied | Trial and follow-up | Average weight loss reported | Important safety context |
|---|---|---|---|
| Semaglutide 2.4 mg once weekly | STEP 1, 68 weeks | 14.9% mean body-weight loss with semaglutide plus lifestyle support vs 2.4% with placebo.[4] | GI side effects were common, and more people stopped treatment due to adverse events with semaglutide than placebo.[4] |
| Tirzepatide 5 mg, 10 mg, or 15 mg once weekly | SURMOUNT-1, 72 weeks | 15.0% to 20.9% mean body-weight loss depending on the studied dose vs 3.1% with placebo.[5] | Nausea, diarrhea, and constipation were common; adverse events led some participants to stop treatment.[5] |
| Liraglutide 3.0 mg once daily | SCALE Obesity and Prediabetes, 56 weeks | 8.0% mean body-weight loss with liraglutide vs 2.6% with placebo.[6] | GI side effects were more common with liraglutide, and the FDA label includes serious warnings and contraindications.[3][6] |
Trial averages are not promises. Some people lose more, some lose less, and some stop because of side effects, cost, access, pregnancy plans, contraindications, or personal preference. Individual results vary.[1][2][3][4][5][6]
What are the side effects and risks?
Peptide injections for weight loss can have real risks, even when they are effective. GLP-1-based medicines have FDA labels with common side effects, rare serious risks, and contraindications; research peptides may have less complete safety data and more quality concerns, especially when bought outside licensed care.[1][2][3][9][12]
Common GI side effects
Common side effects of GLP-1-based weight-loss medicines include nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, and reduced appetite. These effects are often dose-related in trials and labels, and they are a common reason people need follow-up or stop treatment.[1][2][3][4][5][6]
Boxed warnings and contraindications
Semaglutide, tirzepatide, and liraglutide weight-management labels include a boxed warning about thyroid C-cell tumors based on rodent findings. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, also called MEN2.[1][2][3]
FDA labels also describe other risks that need clinician review, including pancreatitis, gallbladder disease, kidney injury related to dehydration, low blood sugar risk when combined with some diabetes medicines, heart rate changes, and suicidal behavior or thinking warnings for some products.[1][2][3]
Risks with unregulated or research-only peptides
Peptides sold online as research chemicals may not have FDA-approved labeling, standard pharmacy oversight, or reliable proof of sterility and potency. That raises risks of contamination, wrong strength, unclear ingredients, and side effects that are not well tracked in human trials.[9][12]
Who is a candidate for peptide injections?
Candidates for GLP-1 weight-loss injections are usually adults who meet FDA label criteria, such as obesity or overweight with at least one weight-related condition. The common BMI thresholds are 30 or higher, or 27 or higher with a qualifying comorbidity, but a clinician must confirm eligibility and safety.[1][2][3]
FDA eligibility criteria
Wegovy, Zepbound, and Saxenda labels include use for chronic weight management in people with obesity, or overweight with at least one weight-related condition, along with a reduced-calorie diet and increased physical activity. Labels define the exact populations studied and approved, including some pediatric use for certain products.[1][2][3]
Who should not use them
People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use semaglutide, tirzepatide, or liraglutide weight-management products. People who are pregnant, planning pregnancy, breastfeeding, have a history of pancreatitis, take certain diabetes medicines, or have significant GI, gallbladder, kidney, or mental health concerns need individualized medical review.[1][2][3]
How do you get peptide injections for weight loss safely?
Getting peptide injections safely starts with a licensed clinician, not an online research-chemical seller. A safe pathway includes screening, prescription review, pharmacy verification, side-effect monitoring, and follow-up over weeks to months, because benefits and risks both change during treatment.[1][2][3][9][12]
Start with a licensed clinician
A clinician should review BMI, weight-related conditions, medical history, family history, current medicines, pregnancy plans, prior pancreatitis or gallbladder disease, and diabetes treatment before prescribing a GLP-1-based medicine. This review helps match the option to the FDA label and avoid known contraindications.[1][2][3]
Branded vs. compounded GLP-1s through a licensed provider
Some people access branded FDA-approved medications such as Wegovy, Zepbound, or Saxenda. Others may be evaluated for compounded semaglutide or compounded tirzepatide through a licensed provider when legal conditions allow. Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1s and longevity peptides through licensed 503A pharmacy partners, with eligibility and treatment decisions made by clinicians.[1][2][3][9]
What a clinical evaluation usually includes
- A review of weight history, goals, medical conditions, and current medications.
- Screening for contraindications, including personal or family history of medullary thyroid carcinoma or MEN2.[1][2][3]
- Discussion of side effects, warning signs, pregnancy considerations, and when to seek care.[1][2][3]
- A plan for follow-up, nutrition, activity, hydration, and monitoring for side effects.
- A prescription sent to an appropriate pharmacy only if the clinician decides treatment is safe and appropriate.
3-min quiz
Considering GLP-1 treatment?
A licensed clinician can review your history, explain branded and compounded options, and help decide whether prescription treatment is appropriate.
Frequently asked questions
Some peptide injections help with weight loss, but mainly the GLP-1-based medicines studied in large trials, such as semaglutide, tirzepatide, and liraglutide. They can also cause side effects and have contraindications, so they require clinician review.[1][2][3][4][5][6]
There is no single best option for everyone. Tirzepatide and semaglutide showed larger average weight loss than liraglutide in major trials, but choice depends on medical history, contraindications, side effects, access, cost, and clinician judgment.[1][2][3][4][5][6]
Ozempic is a peptide medication because it contains semaglutide, a GLP-1 receptor agonist. But peptides are a broad category. Ozempic is FDA-approved for type 2 diabetes, while Wegovy is the semaglutide brand FDA-approved for chronic weight management in eligible people.[1][7]
No. These peptides are not FDA-approved for weight loss and do not have the same large, FDA-reviewed obesity trial evidence as GLP-1-based medicines. Some may be discussed in wellness or research settings, but that is not the same as an approved weight-loss indication.[12]
Public figures' medical care should not be guessed from headlines. The useful takeaway is that weight-loss medications should be discussed based on your own health history, FDA-approved indications, side effects, contraindications, and a licensed clinician's evaluation, not celebrity reports.[1][2][3]
Cost varies by medication, insurance coverage, pharmacy, state rules, and whether the product is branded or compounded. Branded GLP-1s, compounded GLP-1s, visits, labs, and follow-up may be billed differently. Ask for the full monthly cost and what is included before starting.[9]
Obesity is often a chronic condition, and trials studied GLP-1 medicines over many months. Some people continue long term if benefits outweigh risks, while others stop because of side effects, cost, access, pregnancy plans, or personal choice. Stopping can lead to weight regain for some people, so this should be planned with a clinician.[1][2][3][4][5][6][15]
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still must decide whether treatment is appropriate; an AI agent cannot diagnose, prescribe, or replace medical care.
3-min quiz
Learn about prescription options
If you are exploring peptide injections for weight loss, start with an evidence-based clinical evaluation and a clear discussion of benefits, risks, costs, and alternatives.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 2.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2023.
- 3.Novo Nordisk. Saxenda (liraglutide) injection prescribing information. U.S. Food and Drug Administration, 2023.
- 4.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 6.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
- 7.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 8.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 9.U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2025.
- 10.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and 503A Bulks List discussions. U.S. Food and Drug Administration, 2026.
- 11.Theratechnologies. Egrifta SV (tesamorelin) prescribing information. U.S. Food and Drug Administration, 2024.
- 12.American Medical Association. AMA warns patients about use of unapproved injectable weight-loss and body-contouring products. American Medical Association, 2023.
- 13.Sikirić P, Seiwerth S, Rucman R, Kolenc D, Vuletić LB, Drmic D, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2020.
- 14.Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine, 2016.
- 15.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
